High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies
Not available.
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-01-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11898 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841550895862513664 |
|---|---|
| author | Yousef Laham Shimrit Ringelstein-Harlev Daniel Kurnik Riva Fineman Dana Yehudai-Ofir Lilach Bonstein Noga Setter-Marco Eyal Braun Itai Ghersin Tsila Zuckerman Ofrat Beyar-Katz |
| author_facet | Yousef Laham Shimrit Ringelstein-Harlev Daniel Kurnik Riva Fineman Dana Yehudai-Ofir Lilach Bonstein Noga Setter-Marco Eyal Braun Itai Ghersin Tsila Zuckerman Ofrat Beyar-Katz |
| author_sort | Yousef Laham |
| collection | DOAJ |
| description |
Not available.
|
| format | Article |
| id | doaj-art-1b64d43d030e42dcabc1a25edb4b278d |
| institution | Kabale University |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-1b64d43d030e42dcabc1a25edb4b278d2025-01-09T19:43:50ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-01-01999110.3324/haematol.2024.286714High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapiesYousef Laham0Shimrit Ringelstein-Harlev1Daniel Kurnik2Riva Fineman3Dana Yehudai-Ofir4Lilach Bonstein5Noga Setter-Marco6Eyal Braun7Itai Ghersin8Tsila Zuckerman9Ofrat Beyar-Katz10Department of Internal Medicine H, Rambam Health Care Campus, HaifaDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, HaifaSection of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, HaifaDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, HaifaDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, HaifaBlood Bank and Platelet Immunology Laboratory, Rambam Health Care Campus, HaifaDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, HaifaDepartment of Internal Medicine H, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, HaifaDepartment of Internal Medicine H, Rambam Health Care Campus, HaifaDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, HaifaDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa Not available. https://haematologica.org/article/view/11898 |
| spellingShingle | Yousef Laham Shimrit Ringelstein-Harlev Daniel Kurnik Riva Fineman Dana Yehudai-Ofir Lilach Bonstein Noga Setter-Marco Eyal Braun Itai Ghersin Tsila Zuckerman Ofrat Beyar-Katz High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies Haematologica |
| title | High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies |
| title_full | High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies |
| title_fullStr | High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies |
| title_full_unstemmed | High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies |
| title_short | High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies |
| title_sort | high dose intravenous immunoglobulin may be an efficient treatment option for patients with late onset high grade immune effector cell associated hematotoxicity refractory to standard therapies |
| url | https://haematologica.org/article/view/11898 |
| work_keys_str_mv | AT youseflaham highdoseintravenousimmunoglobulinmaybeanefficienttreatmentoptionforpatientswithlateonsethighgradeimmuneeffectorcellassociatedhematotoxicityrefractorytostandardtherapies AT shimritringelsteinharlev highdoseintravenousimmunoglobulinmaybeanefficienttreatmentoptionforpatientswithlateonsethighgradeimmuneeffectorcellassociatedhematotoxicityrefractorytostandardtherapies AT danielkurnik highdoseintravenousimmunoglobulinmaybeanefficienttreatmentoptionforpatientswithlateonsethighgradeimmuneeffectorcellassociatedhematotoxicityrefractorytostandardtherapies AT rivafineman highdoseintravenousimmunoglobulinmaybeanefficienttreatmentoptionforpatientswithlateonsethighgradeimmuneeffectorcellassociatedhematotoxicityrefractorytostandardtherapies AT danayehudaiofir highdoseintravenousimmunoglobulinmaybeanefficienttreatmentoptionforpatientswithlateonsethighgradeimmuneeffectorcellassociatedhematotoxicityrefractorytostandardtherapies AT lilachbonstein highdoseintravenousimmunoglobulinmaybeanefficienttreatmentoptionforpatientswithlateonsethighgradeimmuneeffectorcellassociatedhematotoxicityrefractorytostandardtherapies AT nogasettermarco highdoseintravenousimmunoglobulinmaybeanefficienttreatmentoptionforpatientswithlateonsethighgradeimmuneeffectorcellassociatedhematotoxicityrefractorytostandardtherapies AT eyalbraun highdoseintravenousimmunoglobulinmaybeanefficienttreatmentoptionforpatientswithlateonsethighgradeimmuneeffectorcellassociatedhematotoxicityrefractorytostandardtherapies AT itaighersin highdoseintravenousimmunoglobulinmaybeanefficienttreatmentoptionforpatientswithlateonsethighgradeimmuneeffectorcellassociatedhematotoxicityrefractorytostandardtherapies AT tsilazuckerman highdoseintravenousimmunoglobulinmaybeanefficienttreatmentoptionforpatientswithlateonsethighgradeimmuneeffectorcellassociatedhematotoxicityrefractorytostandardtherapies AT ofratbeyarkatz highdoseintravenousimmunoglobulinmaybeanefficienttreatmentoptionforpatientswithlateonsethighgradeimmuneeffectorcellassociatedhematotoxicityrefractorytostandardtherapies |